1. Home
  2. |Insights
  3. |Perspectives from the Belgian Competition Authority

Perspectives from the Belgian Competition Authority

Event | 03.23.22, 7:30 AM CDT - 9:00 AM CDT

Address

Due to unforeseen circumstances this event is now online only.

In collaboration with the IBJ/IJE

Damien Gerard, the new Prosecutor General of the Belgian Competition Authority (BCA) and Griet Jans, Chief Economist at the BCA since 2020, will provide a snapshot of the BCA’s activities and ongoing projects. In addition to providing a state of play, they will discuss what’s to come for competition law in Belgium and the priorities of the BCA going forward.

Topics covered include:

  • Antitrust: current issues relating to leniency, settlements, commitments, fines and substantive issues such as price signaling and exchange of information
  • Concentrations: gun jumping issues, the increased use of data and economic tools in merger assessment, and general debates surrounding (local) market definitions and efficiencies
  • Recent and upcoming policy initiatives relating to abuse of economic dependency, digitization, sustainability, and labor market issue
  • BCA capacity building in terms of budget, people and instruments

The presentation will be followed by a Q&A session moderated by Crowell & Moring partners Thomas De Meese and Karel Bourgeois. 


If you would like to submit a question beforehand, please reach out to Thomas De Meese at tdemeese@crowell.com and/or Karel Bourgeois at kbourgeois@crowell.com.

For more information, please visit these areas: Antitrust and Competition — Brussels Practice, Brussels Practice, Antitrust and Competition

Insights

Event | 02.25.25

Charting a Path for Compliance in Life Sciences

Join us for an interactive and educational event tailored for biotech leaders seeking to ensure security compliance while leveraging the power of Amazon Web Services (AWS). This session will dive into the critical elements of designing secure, scalable, and compliant systems for biotech operations, from research and development to clinical trials and beyond....